Skip to main content

Table 2 Univariable Cox hazards model analysis of variables for all-cause mortality

From: Clinical implication of plasma exchange on life-threatening antineutrophil cytoplasmic antibody-associated vasculitis

Variables

HR

95% CI

P value

Demographic data at PLEX

 Age

1.007

0.952, 1.064

0.820

 Male gender

1.330

0.186, 9.528

0.777

AAV variants

0.016

0.000, 60.511

0.327

ANCA within 4 weeks before PLEX

 MPO-ANCA

5.710

0.556, 58.595

0.143

 PR3-ANCA

0.027

0.000, 231.881

0.434

 ANCA negativity

0.676

0.069, 6.581

0.736

AAV related indices at PLEX

 BVAS

0.940

0.800, 1.104

0.450

 FFS

1.247

0.423, 3.678

0.689

Clinical manifestations at PLEX

 General

N/A

  

 Cutaneous

0.041

0.000, 5,961,414.0

0.739

 Mucous membrane/Eyes

N/A

  

 ENT

0.024

0.000, 119.450

0.391

 Pulmonary

1.008

0.103, 9.837

0.995

 Cardiovascular

0.491

0.050, 4.786

0.540

 Abdominal

N/A

  

 Renal

0.649

0.067, 6.322

0.710

 Nervous systemic

0.993

0.102, 9.69.

0.995

Reason for PLEX

 DAH vs. RPGN

1.544

0.139, 17.193

0.724

Administered immunosuppressant drugs during follow-up

 CYC

1.893

0.194, 18.490

0.583

 RTX

0.209

0.022, 2.024

0.177

 AZA

7.483

0.467, 119.824

0.155

 MMF

0.038

0.000, 5830.207

0.592

 TAC

N/A

  

 None

1.541

0.158, 15.021

0.710

  1. PLEX plasma exchange, ANCA antineutrophil cytoplasmic antibody, AAV antineutrophil cytoplasmic antibody-associated vasculitis, MPO myeloperoxidase, PR3 proteinase 3, BVAS Birmingham vasculitis activity score, FFS five factor score, ENT ear nose throat, DAH diffuse alveolar haemorrhage, RPGN rapidly progressive glomerulonephritis, CYC cyclophosphamide, RTX rituximab, AZA azathioprine, MMF mycophenolate mofetil, TAC tacrolimus